{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:15:19Z","timestamp":1791249319512,"version":"4.1.0"},"reference-count":30,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIHR Technology Assessment Programme","award":["NIHR129175"],"award-info":[{"award-number":["NIHR129175"]}]},{"name":"National Institute for Health Research EME","award":["16\/167\/19"],"award-info":[{"award-number":["16\/167\/19"]}]},{"DOI":"10.13039\/100008487","name":"Cure Parkinson\u2019s Trust","doi-asserted-by":"publisher","award":["TF03"],"award-info":[{"award-number":["TF03"]}],"id":[{"id":"10.13039\/100008487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR132016"],"award-info":[{"award-number":["NIHR132016"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009128","name":"NIHR Research for Patient Benefit Programme","doi-asserted-by":"crossref","award":["PB-PG-0816-20011"],"award-info":[{"award-number":["PB-PG-0816-20011"]}],"id":[{"id":"10.13039\/501100009128","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["CS\/15\/5\/31475"],"award-info":[{"award-number":["CS\/15\/5\/31475"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["SP\/12\/2\/20422"],"award-info":[{"award-number":["SP\/12\/2\/20422"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","award":["NIHR135419"],"award-info":[{"award-number":["NIHR135419"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,5,27]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To quantify the carbon footprint of a sample of clinical trials for neurological disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      Two clinical trial registries were searched on 29 December 2022 for phase 2\u20134 randomised controlled trials led from and recruiting in the UK, enrolling people with any of the 15 neurological disorders with the highest global burden, that had started recruitment or been registered in the preceding 5 years. Eligible trials were invited to share data to estimate emissions in each of the 10 modules of the Low Carbon Clinical Trials footprinting guidance. The primary outcome measure was kg of carbon dioxide equivalent (CO\n                      <jats:sub>2<\/jats:sub>\n                      e).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      318 randomised controlled trials were found, nine were eligible and six shared data (three completed and three ongoing). The module with the highest estimated CO\n                      <jats:sub>2<\/jats:sub>\n                      e for each trial was the Clinical Trial Unit staff emissions (median 24\u2009126\u2009kg CO2e, IQR 10\u2009395\u201378,867; range 45\u201379% of overall emissions of each trial); commuting accounted for &gt;50% of CO\n                      <jats:sub>2<\/jats:sub>\n                      e in this module. The second and third highest modules were trial-specific participant assessments (median 11\u2009497\u2009kg CO2e, IQR 825\u201315,682) and trial supplies and equipment (median 1161\u2009kg CO\n                      <jats:sub>2<\/jats:sub>\n                      e, IQR 226\u20136632). The total carbon footprint of these six trials involving 2248 participants at 239 sites was 2\u200963\u2009215\u2009kg CO\n                      <jats:sub>2<\/jats:sub>\n                      e.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Emissions by Clinical Trials Unit staff were the top modifiable carbon hotspot in six randomised controlled trials for people with neurological disorders, which had a total carbon footprint equivalent to 1364 passengers\u2019 return aeroplane journeys between London and Edinburgh.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-090419","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T06:20:15Z","timestamp":1750141215000},"page":"e090419","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Carbon footprint of a sample of clinical trials for people with neurological disorders: cross-sectional analysis"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"isrctn79794378","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn67038373","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn14552789","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn14911850","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn98886991","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn71907627","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn14911850","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5360-9950","authenticated-orcid":false,"given":"Denise","family":"Cranley","sequence":"first","affiliation":[{"name":"Edinburgh Clinical Trials Unit, The University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Dunn","sequence":"additional","affiliation":[{"name":"Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Paul","family":"Taylor","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael JR","family":"Desborough","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant, John Radcliffe Hospital, Oxford, Oxfordshire, UK"},{"name":"Oxford Clinical Research in Transfusion Medicine, Univeristy of Oxford, Oxford, Oxfordshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Craig","sequence":"additional","affiliation":[{"name":"Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Sprigg","sequence":"additional","affiliation":[{"name":"Division of Stroke Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"McComish","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0752-1813","authenticated-orcid":false,"given":"Thomas","family":"Foltynie","sequence":"additional","affiliation":[{"name":"Institute of Neurology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Wardlaw","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences & Brain Research Imaging Centre, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Oatey","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, The University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Heye","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, The University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bath","sequence":"additional","affiliation":[{"name":"Division of Stroke Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Innes","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, The University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Dinsmore","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, The University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2406-3796","authenticated-orcid":false,"given":"Jessica","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU), London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Fox","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU), London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula R","family":"Williamson","sequence":"additional","affiliation":[{"name":"Biostatistics, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2108-9222","authenticated-orcid":false,"given":"Rustam","family":"Al-Shahi Salman","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, The University of Edinburgh, Edinburgh, UK"},{"name":"Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"2025121401022397000_15.6.e090419.1","unstructured":"World Health Organisation . Climate change and health research: current trends, gaps and perspectives for the future. Discussion Paper; 2021. Available: https:\/\/www.who.int\/publications\/m\/item\/climate-change-and-health-research-current-trends-gaps-and-perspectives-for-the-future"},{"key":"2025121401022397000_15.6.e090419.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01787-6"},{"key":"2025121401022397000_15.6.e090419.3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(21)01384-2","article-title":"A strategy to reduce the carbon footprint of clinical trials","volume":"398","author":"Adshead","year":"2021","journal-title":"The Lancet"},{"key":"2025121401022397000_15.6.e090419.4","unstructured":"NIHR . NIHR key priorities for climate change and sustainability. 2023. Available: https:\/\/www.nihr.ac.uk\/about-us\/our-key-priorities\/climate-change-sustainability.htm"},{"key":"2025121401022397000_15.6.e090419.5","unstructured":"Academy of Medical Sciences . Enabling greener biomedical research, forum workshop. 2023. Available: https:\/\/acmedsci.ac.uk\/more\/events\/enabling-environmentally-sustainable-biomedical-research"},{"key":"2025121401022397000_15.6.e090419.6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b4187","article-title":"Carbon cost of pragmatic randomised controlled trials: retrospective analysis of sample of trials","volume":"339","author":"Lyle","year":"2009","journal-title":"BMJ"},{"key":"2025121401022397000_15.6.e090419.7","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-12-31","article-title":"Reducing the environmental impact of trials: a comparison of the carbon footprint of the CRASH-1 and CRASH-2 clinical trials","volume":"12","author":"Subaiya","year":"2011","journal-title":"Trials"},{"key":"2025121401022397000_15.6.e090419.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-070200","article-title":"Reducing the carbon footprint of research: experience from the NightLife study","volume":"13","author":"Quann","year":"2023","journal-title":"BMJ Open"},{"key":"2025121401022397000_15.6.e090419.9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-072491","article-title":"Carbon footprint of industry-sponsored late-stage clinical trials","volume":"13","author":"Mackillop","year":"2023","journal-title":"BMJ Open"},{"key":"2025121401022397000_15.6.e090419.10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-085364","article-title":"Climate footprint of industry-sponsored in-human clinical trials: life cycle assessments of clinical trials spanning multiple phases and disease areas","volume":"15","author":"LaRoche","year":"2025","journal-title":"BMJ Open"},{"key":"2025121401022397000_15.6.e090419.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-077129","article-title":"Climate footprint of industry-sponsored clinical research: an analysis of a phase-1 randomised clinical study and discussion of opportunities to reduce its impact","volume":"14","author":"LaRoche","year":"2024","journal-title":"BMJ Open"},{"key":"2025121401022397000_15.6.e090419.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-075755","article-title":"Quantifying the carbon footprint of clinical trials: guidance development and case studies","volume":"14","author":"Griffiths","year":"2024","journal-title":"BMJ Open"},{"key":"2025121401022397000_15.6.e090419.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-088600","article-title":"What is the carbon footprint of academic clinical trials? A study of hotspots in 10 trials","volume":"14","author":"Griffiths","year":"2024","journal-title":"BMJ Open"},{"key":"2025121401022397000_15.6.e090419.14","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(24)00038-3"},{"key":"2025121401022397000_15.6.e090419.15","article-title":"The carbon footprint of hospital diagnostic imaging in Australia","volume":"24","author":"McAlister","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"2025121401022397000_15.6.e090419.16","doi-asserted-by":"publisher","DOI":"10.1080\/00015385.2020.1815985"},{"key":"2025121401022397000_15.6.e090419.17","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.230441","article-title":"Ecodesign and Operational Strategies to Reduce the Carbon Footprint of MRI for Energy Cost Savings","volume":"307","author":"Woolen","year":"2023","journal-title":"Radiology"},{"key":"2025121401022397000_15.6.e090419.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30499-X"},{"key":"2025121401022397000_15.6.e090419.19","unstructured":"World Health Organisation . WHOICTRP data providers. 2023. Available: https:\/\/www.who.int\/clinical-trials-registry-platform\/network\/data-providers"},{"key":"2025121401022397000_15.6.e090419.20","unstructured":"COBALT Trial . A trial to investigate the effect on overall health and functioning in patients with Lewy body dementia of memantine as an add-on treatment to a cholinesterase inhibitor. ISRCTN 2022."},{"key":"2025121401022397000_15.6.e090419.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-037555","article-title":"Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): protocol for a phase II double-blind randomised controlled feasibility trial","volume":"10","author":"Desborough","year":"2020","journal-title":"BMJ Open"},{"key":"2025121401022397000_15.6.e090419.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-047993","article-title":"Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson\u2019s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The \u201cExenatide-PD3\u201d study","volume":"11","author":"Vijiaratnam","year":"2021","journal-title":"BMJ Open"},{"key":"2025121401022397000_15.6.e090419.23","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jamaneurol.2023.1526","article-title":"Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial","volume":"80","author":"Wardlaw","year":"2023","journal-title":"JAMA Neurol"},{"key":"2025121401022397000_15.6.e090419.24","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2022-001816"},{"key":"2025121401022397000_15.6.e090419.25","unstructured":"PhEAST Study . Electrical stimulation of the throat for swallowing difficulties after stroke. 2021."},{"key":"2025121401022397000_15.6.e090419.26","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/S0140-6736(19)30840-2","article-title":"Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial","volume":"393","author":"Al-Shahi Salman","year":"2019","journal-title":"The Lancet"},{"key":"2025121401022397000_15.6.e090419.27","unstructured":"United States Environmental Protection Agency . Greenhouse gas equivalencies calculator. 2023 Available: https:\/\/www.epa.gov\/energy\/greenhouse-gas-equivalencies-calculator#results"},{"key":"2025121401022397000_15.6.e090419.28","unstructured":"CO2 flights Seat 61 . The man in seat 61, CO2 & climate change. 2024. Available: https:\/\/www.seat61.com\/CO2flights.htm"},{"key":"2025121401022397000_15.6.e090419.29","doi-asserted-by":"crossref","first-page":"117579","DOI":"10.1016\/j.jns.2021.117579","article-title":"Neurology trial registrations on ClinicalTrials.gov between 2007 and 2018: A cross-sectional analysis of characteristics, early discontinuation, and results reporting","volume":"428","author":"Turner","year":"2021","journal-title":"J Neurol Sci"},{"key":"2025121401022397000_15.6.e090419.30","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.019227"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-090419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:02:35Z","timestamp":1765702955000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-090419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,17]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/bmjopen-2024-090419"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-090419","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}